Journal
SCIENCE
Volume 335, Issue 6075, Pages 1503-1506Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1217697
Keywords
-
Categories
Funding
- Blanchette Hooker Rockefeller Foundation
- Thome Foundation
- Roby and Taft Funds for Alzheimer's Research
- Painstone Foundation
- American Health Assistance Foundation
- Cure Alzheimer's Fund
- Coins for Alzheimer's Research Trust
- National Institute on Aging (NIA) [AG030482-03S1]
- National Institute on Deafness and Other Communication Disorders [DC003906, RO1-AG037693]
- NIA [K01 AG029524, P50-AG005681]
- Shmerler family
- Charles F. and Joanne Knight Alzheimer's Disease Research Center at Washington University
- Marian S. Ware Alzheimer Program
Ask authors/readers for more resources
Alzheimer's disease (AD) is associated with impaired clearance of beta-amyloid (A beta) from the brain, a process normally facilitated by apolipoprotein E (apoE). ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator-activated receptor gamma and liver X receptors in coordination with retinoid X receptors (RXRs). Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble A beta within hours in an apoE-dependent manner. A beta plaque area was reduced more than 50% within just 72 hours. Furthermore, bexarotene stimulated the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Thus, RXR activation stimulates physiological A beta clearance mechanisms, resulting in the rapid reversal of a broad range of A beta-induced deficits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available